Publication
Epidemiologia da Demência e da Doença de Alzheimer em Portugal: Estimativas da Prevalência e dos Encargos Financeiros com a Medicação
dc.contributor.author | Santana, Isabel | |
dc.contributor.author | Farinha, Filipa | |
dc.contributor.author | Freitas, Sandra | |
dc.contributor.author | Rodrigues, Vitor | |
dc.contributor.author | Carvalho, Álvaro | |
dc.date.accessioned | 2015-10-08T14:25:52Z | |
dc.date.available | 2015-10-08T14:25:52Z | |
dc.date.issued | 2015 | |
dc.description.abstract | Introduction: The incidence and prevalence of global dementia and Alzheimer’s disease (AD) increase with age, almost doubling every five years after the sixth decade of life. Demographic aging is a reality in Portugal, being expectable that the number of dementia cases also increases. Even so, dementia-epidemiological data in Portugal is scarce and cost-of-illness studies are almost inexistent. Our aims were to obtain up-to-date information about the prevalence of dementia/ Alzheimer’s disease in Portugal, to estimate the number of cases effectively diagnosed as Alzheimer’s disease and to determine illness-costs with specific dementia treatment. Material and Methods: The numbers of age-adjusted prevalence of dementia obtained for Occidental Europe (Alzheimer’s Disease International study), where applied to the resident population in Portugal (2013). Estimations related to diagnosis and treatment-costs were based in data provided by the Intercontinental Marketing Services Health (IMSH) – 2013. Results: The estimated number of Portuguese people with dementia among those aged ≥ 60 years, is 160287, representing 5.91% of this population-stratum. Knowing Alzheimer’s disease is responsible for 50-70% of all cases, we might conclude there are between 80144 and 112201 patients. According to IMSH-data, 76250 receive anti-dementia drugs and the costs of this kind of medication is 37 M€/year. Conclusions: As a consequence of the demographic aging, also the number of dementia cases increases. Aparentely, not all Alzheimer’s disease patients receive the recommended medication, suggesting this condition is still under-diagnosed. However, figures indicate a positive progression with an increment of treated cases and a reduction of medication-costs. | pt_PT |
dc.identifier.issn | 1646-0758 | |
dc.identifier.uri | http://hdl.handle.net/10400.26/9884 | |
dc.language.iso | por | pt_PT |
dc.peerreviewed | yes | pt_PT |
dc.publisher | Ordem dos Médicos | pt_PT |
dc.relation.publisherversion | http://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/6025/4295 | pt_PT |
dc.subject | Doença de Alzheimer | pt_PT |
dc.subject | Custos | pt_PT |
dc.subject | Epidemiologia | pt_PT |
dc.subject | Portugal | pt_PT |
dc.title | Epidemiologia da Demência e da Doença de Alzheimer em Portugal: Estimativas da Prevalência e dos Encargos Financeiros com a Medicação | pt_PT |
dc.title.alternative | The Epidemiology of Dementia and Alzheimer Disease in Portugal: Estimations of Prevalence and Treatment-Costs | pt_PT |
dc.type | journal article | |
dspace.entity.type | Publication | |
oaire.citation.conferencePlace | Lisboa | pt_PT |
oaire.citation.endPage | 188 | pt_PT |
oaire.citation.issue | 2 | pt_PT |
oaire.citation.startPage | 182 | pt_PT |
oaire.citation.title | Acta Médica Portuguesa | pt_PT |
oaire.citation.volume | 28 | pt_PT |
rcaap.rights | openAccess | pt_PT |
rcaap.type | article | pt_PT |